Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark, 5000
- Odense University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria
- Patients must have Multiple Myeloma
- Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade
- Patients must be able to understand and speak Danish
- Patients must have received a minimum of 1 treatment cycle in the outpatient clinic
Exclusion criteria
- Lack of willingness to participate in scheduled interviews
- Patients who are cognitively affected
- Must not be receiving trial treatment
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients experience of self-administration of Velcade
Time Frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Qualitative interviews with all 10 included patients
|
Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Organizational perspective
Time Frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Patients and health professionals (including pharmacy staff) registration of time spend on treatment on all 10 included patients.
|
Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
|
Health care perspective
Time Frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Focus group interview with healthcare professionals involved in the treatment.
|
Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
|
Financial perspective
Time Frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Evaluation of financial savings on home treatment including healthcare salaries and transportation.
|
Through study completion, from 01. dec. 2019 until 01. jun. 2022
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Karin Brochstedt Dieperink, RN, Odense University Hospital. Department of Oncology.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Bortezomib
Other Study ID Numbers
Other Study ID Numbers
- Velcade at home
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.